Emergent BioSolutions: The path to re-emergence

Emergent BioSolutions was arguably one batch away from being a pandemic hero. 

Just months after COVID-19 gripped the world, the Maryland-based life sciences company had locked in deals to manufacture two of the five leading Operation Warp Speed vaccine candidates. 

Shortly after Emergent had inked what eventually became a five-year deal worth at least $480 million with Johnson & Johnson to produce bulk drug substance for Janssen’s vaccine candidate, the U.S. government issued a $628 million task order to reserve capacity for a second OWS innovator — AstraZeneca. This resulted in Emergent signing an additional $261 million deal to make drug substances for the AstraZeneca-Oxford vaccine candidate. 

Read the full article at: www.pharmamanufacturing.com